Physicians and researchers from leading institutions convened at the
American Society of Clinical Oncology’s (ASCO) 2016 Annual Meeting to
collaborate on the development of combination immunotherapy clinical
trial protocols for patients with breast cancer
Key thought leaders to accelerate immunotherapy and precision
medicine through GPS Cancer™
CULVER CITY, Calif.--(BUSINESS WIRE)--
Cancer
MoonShot 2020, the nation's most comprehensive cancer
collaborative initiative, today announced the formation of the Breast
Cancer Working Group. The team consists of physicians, researchers and
oncology professors from across the nation who have come together to
focus their collective wisdom and expertise to identify and develop the
most effective cancer-directed immunotherapy treatments for breast
cancer.
Experts within the group will collaborate to develop clinical trial
protocols, carefully studying elements such as standard of care, GPS
Cancer test factors, patient selection, and appropriate combination
immunotherapy approaches. GPS Cancer, offered by NantHealth, is a
unique, comprehensive test integrating quantitative proteomics, and
whole genome (DNA) and transcriptome (RNA) sequencing of tumor and
normal germline samples to provide oncologists with a comprehensive
molecular profile of a patient’s cancer to inform personalized treatment
strategies and identify therapies that may have clinical benefit for the
patient, including Quantitative Integrative Lifetime Trials (QUILT). GPS
Cancer is performed in the CLIA-certified, CAP-accredited laboratories
of NantOmics.
Key benefits of the Working Group branches of study include:
-
Physicians and professionals bring their expertise and combined years
of knowledge and understanding from within a specific disease study to
the collective;
-
Integrated research;
-
Real-time communication of current data;
-
Access to the most cutting edge technology available in immunotherapy
research to date; and,
-
A keen familiarity with the special needs of patients with specific
cancers
“Building a collaborative group of thought leaders and visionaries who
are committed to fighting breast cancer is essential to the overall
efforts of Cancer MoonShot 2020,” explained Patrick Soon-Shiong, M.D.,
founder and CEO of NantWorks and leader of the Cancer MoonShot 2020
program. “I am thrilled that this group of experts have joined forces to
work together to ensure that development of next generation diagnostics
and combination immunotherapies will be accelerated to transform the way
breast cancer is treated.”
The Breast Cancer Working Group was chaired by William Gradishar, MD,
Professor of Medicine and Deputy Chief of the Division of Hematology /
Oncology at Northwestern University Feinberg School of Medicine and
Director of the Lurie Cancer Center’s Maggie Daley Center for Women’s
Cancer Care, who will spearhead the team’s efforts with regular meetings
and development of protocols announced at the American
Society of Clinical Oncology's (ASCO) 2016 Annual Meeting.
“The Cancer MoonShot 2020 Breast Cancer Working Group brings together
leaders in Breast Cancer with interests in developmental therapeutics,
laboratory research and clinical evaluation of novel approaches for
treating patients with cancer. A theme that will focus our mission is to
design and rapidly implement clinical trials that focus on immune
approaches with novel targeted compounds, vaccines and standard
therapies. We are committed to identifying new therapies that will
improve the outcome for all our patients,” said Dr. Gradishar of the
newly formed group.
Other esteemed members of the Working Group include:
-
Peter Fasching, MD, Comprehensive Cancer Center
Erlangen-EMN, Friedrich-Alexander University Erlangen,
Associate Professor of Gynecology and Obstetrics and Translational
Medicine
-
Massimo Cristofanilli, MD, FACP, Associate Director of
Precision Medicine and Translational Research at the Lurie Cancer
Center and Professor of Medicine in the Division of
Hematology/Oncology at Northwestern University Feinberg School of
Medicine
-
Jenny Chang, MD, Houston Methodist
-
Nora Disis, MD, University of Washington Medicine,
Professor of Medicine
-
Eleftherios (Terry) Mamounas, MD, University of Florida Health
Cancer Center, Orlando Health
-
Ruth O'Regan, MD, University of Wisconsin, Professor and
Division Chief of Hematology and Oncology
-
George Somlo, MD, Professor in the Departments of Medical
Oncology & Therapeutics Research and Hematology & Hematopoietic Cell
Transplantation and President-Elect of the Medical Staff at City of
Hope Medical Center
-
Dennis Sgroi, MD, Pathologist and Director of Breast
Pathology at Massachusetts General Hospital and Professor of Pathology
at Harvard Medical School
-
Sunil Badve, MD, FRCPath, Joshua Edwards Professor of
Pathology & Laboratory Medicine and Professor of Internal Medicine at
the Indiana University School of Medicine
“Our goal with this Working Group is to put combination immunotherapy in
the forefront as the approach to improve long-term treatment response in
cancer patients,” stated Massimo Cristofanilli, MD, Associate Director
for Precision Medicine and Translational Research and Precision Medicine
at the Lurie Cancer Center. “The establishment of this Working Group
marks another milestone in win the war on cancer and I am thrilled to be
a part of the Cancer MoonShot 2020 initiative.”
About Cancer MoonShot 2020
The Cancer MoonShot 2020 program is one of the most comprehensive cancer
collaborative initiative launched to date, seeking to accelerate the
potential of combination immunotherapy as the next generation standard
of care in cancer patients. This initiative aims to explore a new
paradigm in cancer care by initiating randomized Phase II trials in
patients at all stages of disease in 20 tumor types in 20,000 patients
within the next 36 months. These findings will inform Phase III trials
and the aspirational moonshot to develop an effective vaccine-based
immunotherapy to combat cancer by 2020. For more information, please
visit www.cancermoonshot2020.org and
follow Cancer MoonShot 2020 on Twitter.
About GPS Cancer™
GPS Cancer™ is a unique, comprehensive test available through
NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole
transcriptome (RNA) sequencing, and quantitative proteomics through mass
spectrometry, providing oncologists with a comprehensive molecular
profile of a patient’s cancer to inform personalized treatment
strategies. GPS Cancer testing is conducted in the CLIA-certified,
CAP-accredited laboratories of NantOmics, and is a key enabler for
Cancer MoonShot 2020, the world’s most comprehensive cancer
collaborative initiative seeking to accelerate the potential of
combination immunotherapy as the next generation standard of care in
cancer patients. For more information, visit www.gpscancer.com
and http://www.cancermoonshot2020.org/.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160607005752/en/
NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com
Source: NantHealth, LLC